BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Xantho Biotechnology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Xantho Biotechnology's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06620692-1373@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:GM-XANTHO: Phase 2 readout est. (NCT06620692)
DESCRIPTION:GM-XANTHO\, phase 2\, Psoriasis.\nStudy: A Study to Investigate
  the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With
  Psoriasis\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gm-xantho#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06620692
URL:https://assetmemo.bio/drug/gm-xantho#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05199077-1373@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:GM-XANTHO: Phase 2 readout est. (NCT05199077)
DESCRIPTION:GM-XANTHO\, phase 2.\nStudy: A Study of GM-XANTHO in Pressure U
 lcer Patients\nEstimated primary completion: 31 December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gm-xantho#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05199077
URL:https://assetmemo.bio/drug/gm-xantho#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
